Clinical response to rituximab therapy in AIHA was found to be associated with decrease in Th1 cytokines interferon-γ, interleukin-12, tumor necrosis factor-α, and IL-17, suggesting immunomodulatory activity of rituximab on Th1/Th2 balance [61]. This evidence concerns the gene IL17A and autoimmune hemolytic anemia.